- Biopharmaceutical company Innovent Biologics (OTCPK:IVBIY) and IASO Biotechnology enter agreement under which IASO will purchase Innovent’s (OTCPK:IVBIY) relevant rights of FUCASO under the original “BCMA CAR-T Cell Therapy Cooperation Agreement” at the agreed price and Innovent (OTCPK:IVBIY) will use the proceeds to acquire an 18% stake in IASO Bio.
- Under the new strategic cooperation framework, the parties will achieve high-level integration in the field of cellular immunotherapy.
- The new model will endow more integrated resources and dedicated team in the full chain of manufacturing, development and commercial operation of CAR-T cell therapy as a special novel modality. Also, we will continue to support IASO Bio as a strategic shareholder. We look forward to working with IASO Bio to improve the accessibility of medications and bring hope to patients worldwide.” said Dr. Michael Yu, Founder, Chairman and CEO of Innovent.
2024-07-05